PE Guidelines logo

Pharmacoeconomic Guidelines Around The World

Country/Region: Malaysia

PE Guidelines
Pharmacoeconomic Guideline For Malaysia (March 2012)
Pdf in English

PE Guidelines Source:
Ministry of Health of Malaysia

Additional Information:

Last Webpage Update: Thursday, April 28, 2016

PE Guidelines Key Features:
Key Features:  
Title and year of the documentPharmacoeconomic Guideline For Malaysia 2012 
Affiliation of authorsPSD, MOH, MaHTAS, MySPOR, MPS,MUSC,UM,UKM,UKMMC, USM, UNU-IIGH, UiTM 
Purpose of the documentA methodological guide to conduct pharmacoeconomic analysis in Malaysia.  
Standard reporting format includedYes 
DisclosureYes 
Target audience of funding/ authorís interestsBoth public and private payers, healthcare industries, clinicians, and research communities, accordingly. 
PerspectiveProvider or funder. Patient and societal perspective are encouraged 
IndicationIndication(s) must be approved by DCA/reference country 
Target populationMust be clearly stated. 
Subgroup analysisYes, can be included when appropriate 
Choice of comparatorTo be compared against the most relevant alternatives for the proposed indication in the applied setting. Comparator(s) should not be a placebo but non-drug therapy can be used. The choice of comparator(s) should always be justified. 
Time horizonShould be long enough to capture all changes in cost(s) and outcome(s) of the intervention. 
Assumptions requiredYes. Should be clearly stated. 
Preferred analytical techniqueCEA and CUA. Technique chosen should be justified clearly. 
Costs to be includedAll costs relevant to the chosen perspective (provider/funder). Societal cost is preferred in any analysis. 
Source of costsLocal cost data in the applied setting. The source of cost data must be identified. 
ModelingYes. Clearly detailed with maximum transparency. All assumptions should be explicitly stated. 
Systematic review of evidencesYes. Meta-analysis is encouraged. 
Preference for effectiveness over efficacyN/A 
Preferred outcome measureShould justify the selection. 
Preferred method to derive utilityShould justify the selection. 
Equity issues statedN/A 
Discounting costs3% (Sensitivity Analysis, 0 and 5%) 
Discounting outcomes3% (Sensitivity Analysis, 0 and 5%) 
Sensitivity analysis-parameters and rangeAll key uncertain parameters. Best and worst case scenario presented. 
Sensitivity analysis-methodsOne-way, multivariate analysis as deemed appropriate. 
Presenting resultsAggregated and disaggregated form for cost(s) and outcome(s). 
Incremental analysisYes 
Total costs vs effectiveness (cost/effectiveness ratio)Yes 
Portability of results (Generalizability)N/A 
Financial impact analysisYes 
Mandatory or recommended or voluntaryVoluntary for 2 years upon launch of the pharmacoeconomic guideline and mandatory thereafter. 

Acknowledgement: The ISPOR Malaysia Chapter (MySPOR) contributed to the key feature form.

Country Selection Page  |  PE Guidelines Index Page